Approach to the Patient: Diagnosis of Cushing Syndrome
Open accessThe DOI matches its Crossref record; 96 of the 100 references it cites were found in a registry or an index; 50 of the 202 sources its claims cite were checked for support.
Abstract
Cushing syndrome results from supraphysiological exposure to glucocorticoids and is associated with significant morbidity and mortality. The pathogenesis includes administration of corticosteroids (exogenous Cushing syndrome) or autonomous cortisol overproduction, whether or not ACTH-dependent (endogenous Cushing syndrome). An early diagnosis of Cushing syndrome is warranted; however, in clinical practice, it is very challenging partly because of resemblance with other common conditions (ie, pseudo-Cushing syndrome). Initial workup should start with excluding local and systemic corticosteroid use. First-line screening tests including the 1-mg dexamethasone suppression test, 24-hour urinary free cortisol excretion, and late-night salivary cortisol measurement should be performed to screen for endogenous Cushing syndrome. Scalp-hair cortisol/cortisone analysis helps in the assessment of long-term glucocorticoid exposure as well as in detection of transient periods of hypercortisolism as observed in cyclical Cushing syndrome. Interpretation of results can be difficult because of individual patient characteristics and hence requires awareness of test limitations. Once endogenous Cushing syndrome is established, measurement of plasma ACTH concentrations differentiates between ACTH-dependent (80%-85%) or ACTH-independent (15%-20%) causes. Further assessment with different imaging modalities and dynamic biochemical testing including bilateral inferior petrosal sinus sampling helps further pinpoint the cause of Cushing's syndrome. In this issue of "Approach to the patient," the diagnostic workup of Cushing syndrome is discussed with answering the questions when to screen, how to screen, and how to differentiate the different causes. In this respect, the latest developments in biochemical and imaging techniques are discussed as well.
Overview
CoChat Summary
## TL;DR
This article is a clinical review of how to diagnose Cushing syndrome, emphasizing when to screen, how to interpret first-line tests, and how to distinguish pseudo-Cushing, ACTH-dependent, ACTH-independent, and pregnancy-related cases. It uses two cases to illustrate common diagnostic pitfalls, including anticonvulsant interference with dexamethasone testing and intermediate ACTH values that require additional biochemical and imaging workup.
## Key findings
- Cushing syndrome is associated with serious morbidity and mortality; the paper states a 3.5 to 5 times increased mortality risk versus the general population, and the risk of myocardial infarction is about 4.5 times higher.
- Endogenous Cushing syndrome is estimated to have an incidence of 0.2 to 5.0 per million people per year and a prevalence of 39 to 79 per million; 80% to 85% of cases are ACTH-dependent and 15% to 20% are ACTH-independent.
- First-line screening tests recommended are 1-mg dexamethasone suppression test (DST), 24-hour urinary free cortisol (UFC), and late-night salivary cortisol (LNSC); UFC and LNSC should be done at least twice because of day-to-day variation.
- In the hair-cortisol section, the paper reports hair cortisone had 87% sensitivity and 90% specificity, compared with hair cortisol at 81% sensitivity and 88% specificity, for distinguishing Cushing syndrome in the cited studies.
## Methods
- This is an expert clinical review in the “Approach to the Patient” format, organized around diagnostic questions: when to screen, how to screen, and how to differentiate causes of Cushing syndrome.
- The paper draws on two illustrative cases: case 1 involved a 45-year-old woman with suspected pseudo-Cushing syndrome and case 2 a 52-year-old woman with adrenal imaging findings, venous thrombosis, and ultimately pituitary-dependent Cushing syndrome.
- The main analysis is a narrative synthesis of diagnostic strategies using biochemical tests (DST, UFC, LNSC, ACTH, DHEAS, CRH testing, dexamethasone-CRH testing), imaging (pituitary MRI, adrenal CT/MRI, PET), and bilateral inferior petrosal sinus sampling.
## Limitations
- The paper states that all tests have caveats and interpretation requires awareness of individual patient characteristics and test limitations.
- It explicitly notes that the hair cortisol/cortisone method is not yet widely available and is still a relatively novel diagnostic tool.
- Evident from the text: this is a review with illustrative cases, not a primary diagnostic accuracy study of all recommended tests, so some performance figures are drawn from cited prior studies rather than generated directly in this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
39 Valid · 2 Not valid · 70 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ACTH-dependent CS accounts for 80% to 85% of cases and ACTH-independent accounts for 15% to 20% (2, 4, 5).”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > Learning points
What the sources say
- Not checked — no full text of the sourcecites [2] Lacroix, 2015, Cushing’s syndrome, Lancet source
- Not checked — no full text of the sourcecites [4] Pivonello, 2008, Cushing’s syndrome, Endocrinol Metab Clin North Am source
- Partly supportedcites [5] Sharma, 2015, Cushing’s syndrome: epidemiology and developments in disease management, Clin Epidemiol sourceExperimental — accuracy not yet measured
The Classification of Cushing’s syndrome section states that ACTH-independent disease accounts for 15%–20% of endogenous Cushing’s syndrome in adults. The citing sentence gives the same percentage but does not specify those limits, so the source does not establish it for all Cushing syndrome cases. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“ACTH-dependent CS accounts for 80% to 85% of cases and ACTH-independent accounts for 15% to 20% (2, 4, 5).”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > Learning points
What the sources say
- Not checked — no full text of the sourcecites [2] Lacroix, 2015, Cushing’s syndrome, Lancet source
- Not checked — no full text of the sourcecites [4] Pivonello, 2008, Cushing’s syndrome, Endocrinol Metab Clin North Am source
- Supportedcites [5] Sharma, 2015, Cushing’s syndrome: epidemiology and developments in disease management, Clin Epidemiol source
The Classification of Cushing’s syndrome section states directly that ACTH-dependent disease accounts for 80%–85% of cases. Its context specifies endogenous Cushing’s syndrome. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients often present with nonspecific features such as (abdominal) obesity and weight gain, rounded (moon) face, menstrual irregularity, and depression (1, 3, 5) as depicted in Figure 1.”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > When to Screen
What the sources say
- Not matchedcites [1] Agrawal, 2021
We searched by its title and found no matching paper.
- Supportedcites [3] Nieman, 2008, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab. source
Section 1.0 says patients more often have features common in the general population, including obesity, depression, and menstrual irregularity. Table 1 also lists weight gain and facial fullness among common or less discriminatory features of Cushing’s syndrome, supporting the description of nonspecific presentation. Page numbers are not provided in our copy. (LLM, conf=0.89)
- Partly supportedcites [5] Sharma, 2015, Cushing’s syndrome: epidemiology and developments in disease management, Clin Epidemiol sourceExperimental — accuracy not yet measured
The Clinical features section identifies weight gain as the most common sign, says increased visceral adipose tissue is common, and describes menstrual irregularity and depression in patients with Cushing’s syndrome. It also says no single symptom is pathognomonic, consistent with the claim that these features are nonspecific. The passages from our copy do not mention a rounded or “moon” face. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“Regarding the 1-mg DST, it is essential to screen for current drug use, which could alter dexamethasone clearance and/or levels of cortisol-binding globulin.”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > How to Screen/Establishment of Hypercortisolism
What the sources say
- Supportedcites [3] Nieman, 2008, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab. source
The Remarks for dexamethasone tests state that anticonvulsants including phenytoin and carbamazepine increase dexamethasone clearance, affecting the 1-mg DST. The same section says oral contraceptives increase cortisol-binding globulin and can cause false-positive results. Page numbers are not shown in the supplied passages. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These relations between corticosteroid use and cardiometabolic sequelae seemed to be related to glucocorticoid receptor gene variants that are associated with increased or normal glucocorticoid sensitivity.”
§ Approach to the Patient: Diagnosis of Cushing Syndrome > Exogenous Steroids
What the sources say
- Could not verifycites [37] Savas, 2017, Associations between systemic and local corticosteroid use with metabolic syndrome and body mass index, J Clin Endocrinol Metab. sourceExperimental — accuracy not yet measured
Our copy of Savas et al. (2017) reports the associations between corticosteroid (CS) use and cardiometabolic traits (metabolic syndrome, BMI), especially in women and in systemic/inhaled users (Discussion; Sensitivity analyses), but it nowhere attributes those relations to glucocorticoid receptor gene variants. The mechanisms it does discuss are non-genetic: sex differences in susceptibility, drug absorption/distribution/metabolism/elimination, adherence, CS-induced reductions in estrogen and testosterone, visceral/gynoid fat distribution, and the high receptor affinity and pharmacokinetics of budesonide/fluticasone (Discussion, refs 14-35). Searches for 'glucocorticoid receptor gene variants', 'polymorphism/genetic variation in sensitivity', and 'NR3C1 / individual susceptibility / limitations' returned no passage on genetic glucocorticoid sensitivity; the Study design section mentions the cohort's 'complex genetics' focus only in describing Lifelines, and the Limitations paragraph lists cross-sectional design, confounding by indication and residual confounding, not genotype. (LLM, conf=0.72)
- Partly supportedcites [38] Savas, 2020, Systemic and local corticosteroid use is associated with reduced executive cognition, and mood and anxiety disorders, Neuroendocrinology sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports an association between corticosteroid use and adverse cardiometabolic outcomes. Neither that passage nor the Discussion's account of systemic effects links those outcomes to glucocorticoid receptor gene variants or to increased or normal glucocorticoid sensitivity; searches for those terms found no such passage. (LLM, conf=0.83)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
76 more claims · 24 with their cited sources checked
Create a free account to see all 129 claims and to verify the 46 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 10
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 10×
“Patients who have multiple symptoms, which are progressive over time, in particular when specific cushingoid features are present (3).”
BackgroundInfluentialMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“The prevalence and pathophysiology of comorbidities in CS (5, 10, 14-28) are shown in Table 1.”
BackgroundConsensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Moreover, it is also important to screen for concomitant use of other drugs such as antifungals, protease inhibitors, or estrogens given the potential drug–drug interaction resulting in increased glucocorticoid effect (32, 33).”
BackgroundChronic stress and comfort foods: Self-medication and abdominal obesity
Dallman, M. F., Pecoraro, N. C., & la Fleur, S. E. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2004.11.004 · Cited by 656 · cited 2×
“The prevalence and pathophysiology of comorbidities in CS (5, 10, 14-28) are shown in Table 1.”
BackgroundComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
Freda, P. U., Beckers, A. M., Katznelson, L., Molitch, M. E., Montori, V. M., Post, K. D., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1048 · Cited by 585
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419 · cited 3×
“Finally, patients with active CS have a high risk of venous thromboembolism (VTE) in comparison to the general population (8, 45, 46).”
BackgroundDi Dalmazi, G., Vicennati, V., Garelli, S., Casadio, E., Rinaldi, E., Giampalma, E., Mosconi, C., Golfieri, R., Paccapelo, A., Pagotto, U., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70211-0 · Cited by 415
ROSS, E. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92749-0 · Cited by 390 · cited 1×
“Clinical features such as ecchymoses, proximal myopathy, wide reddish-purple striae, facial plethora, recurrent infections, and osteopenia have been found to be more characteristic of CS (41, 42) and aid in the decision to perform screening tests.”
BackgroundCushing’s Syndrome during Pregnancy: Personal Experience and Review of the Literature
Lindsay, J. R., Jonklaas, J., Oldfield, E. H., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2361 · Cited by 343 · cited 3×
“Suppression of serum and plasma cortisol by dexamethasone is blunted during pregnancy; therefore, making the DST difficult to interpret in these patients (3, 90, 92).”
BackgroundDiagnosis and Management of Cushing’s Syndrome: Results of an Italian Multicentre Study 1
Invitti, C., Giraldi, F. P., De Martin, M., & Cavagnini, F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5465 · Cited by 336
Glucocorticoid sensitivity in health and disease
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van Rossum, E. F. C., & Feelders, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.183 · Cited by 310
Self-citationHair cortisol analysis: An update on methodological considerations and clinical applications
Greff, M. J. E., Levine, J. M., Abuzgaia, A. M., Elzagallaai, A. A., Rieder, M. J., & van Uum, S. H. M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.09.010 · Cited by 260 · cited 1×
“Depending on the length of the collected hair sample, it is possible to make timelines of past glucocorticoid exposure (64).”
BackgroundSystemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events
Fardet, L., & Fève, B. (2014) · Drugs · doi:10.1007/s40265-014-0282-9 · Cited by 236
Young, J., Haissaguerre, M., Viera-Pinto, O., Chabre, O., Baudin, E., & Tabarin, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0877 · Cited by 232 · cited 7×
“Patients with EAS are typically unresponsive although some tumors, in particular bronchial carcinoids can express CRH receptors (9, 74, 81, 82).”
BackgroundMethodInfluentialAccuracy of Diagnostic Tests for Cushing’s Syndrome: A Systematic Review and Metaanalyses
Elamin, M. B., Murad, M. H., Mullan, R., Erickson, D., Harris, K., Nadeem, S., Ennis, R., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0139 · Cited by 222 · cited 2×
“The likelihood ratios (LRs) for the first-line screening tests and scalp hair analysis concern pooled data from (47) and findings from (48), respectively.”
BackgroundHair analysis provides a historical record of cortisol levels in Cushing's syndrome
Thomson, S., Koren, G., Fraser, L.-A., Rieder, M., Friedman, T. C., & Van Uum, S. H. M. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1220771 · Cited by 218 · cited 1×
“Because hair can be used as a historical timeline, scalp hair cortisol analysis can also be useful in studying the onset of CS (eg, in ectopic CS) or cyclic CS (59, 68).”
BackgroundHypercoagulable State in Cushing’s Syndrome: A Systematic Review
Van Zaane, B., Nur, E., Squizzato, A., Dekkers, O. M., Twickler, M. (. B., Fliers, E., Gerdes, V. E. A., Büller, H. R., & Brandjes, D. P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0290 · Cited by 216
Cushing's disease: pathobiology, diagnosis, and management
Lonser, R. R., Nieman, L., & Oldfield, E. H. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152119 · Cited by 215 · cited 1×
“Cushing disease, the most common cause of ACTH-dependent CS accounting for approximately 80% of cases, occurs when a pituitary adenoma secretes ACTH, which in turn stimulates supraphysiologic secretion of cortisol from the adrenal glands (2, 4, 5, 73).”
BackgroundClinical applications of cortisol measurements in hair
Wester, V. L., & van Rossum, E. F. C. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0313 · Cited by 210 · cited 1×
“In the past decade, great progress has been made with the development of scalp hair glucocorticoid analysis, although this method is not yet widely available (65).”
MethodCushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210 · cited 9×
“Based on Agrawal et al (1), Sharma et al (5), and Pivonello et al (27).”
BackgroundMethodInfluentialSelf-citationIncidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208 · cited 1×
“Finally, patients with active CS have a high risk of venous thromboembolism (VTE) in comparison to the general population (8, 45, 46).”
BackgroundSelf-citationMEIKLE, A. W. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb00733.x · Cited by 201 · cited 1×
“In case of positive DST, measurement of serum dexamethasone concentration could be of value in identifying insufficient levels (53) (eg, from altered dexamethasone metabolism or inadequate test adherence) and in determining in whom a second DST would be useful (54).”
BackgroundCharmandari, E., Kino, T., Ichijo, T., & Chrousos, G. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0040 · Cited by 201 · cited 1×
“Primary glucocorticoid resistance, a rare genetic condition resulting mainly from mutations in the glucocorticoid receptor gene, would on the contrary yield abnormal test results (51).”
BackgroundApproach to the Patient With Adrenal Incidentaloma
Bancos, I., & Prete, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab512 · Cited by 201
Pivonello, R., De Martino, M. C., De Leo, M., Lombardi, G., & Colao, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.010 · Cited by 195
Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome
Pivonello, R., De Leo, M., Vitale, P., Cozzolino, A., Simeoli, C., De Martino, M. C., Lombardi, G., & Colao, A. (2010) · Neuroendocrinology · doi:10.1159/000314319 · Cited by 190
Pathophysiology of Dyslipidemia in Cushing’s Syndrome
Arnaldi, G., Scandali, V. M., Trementino, L., Cardinaletti, M., Appolloni, G., & Boscaro, M. (2010) · Neuroendocrinology · doi:10.1159/000314213 · Cited by 189
The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome
Pivonello, R., Faggiano, A., Lombardi, G., & Colao, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.010 · Cited by 173
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment
van der Pas, R., Leebeek, F. W. G., Hofland, L. J., de Herder, W. W., & Feelders, R. A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12094 · Cited by 162
Self-citationThe Immune System in Cushing’s Syndrome
Hasenmajer, V., Sbardella, E., Sciarra, F., Minnetti, M., Isidori, A. M., & Venneri, M. A. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.04.004 · Cited by 147
Neuropsychiatric Disorders in Cushing’s Syndrome
Pereira, A. M., Tiemensma, J., & Romijn, J. A. (2010) · Neuroendocrinology · doi:10.1159/000314317 · Cited by 145
Cushing's syndrome: epidemiology and developments in disease management
Sharma, S. T., Nieman, L. K., & Feelders, R. A. (2015) · Dove Medical Press (Taylor and Francis Group) · Cited by 138
Self-citationCushing’s syndrome: from physiological principles to diagnosis and clinical care
Raff, H., & Carroll, T. (2015) · The Journal of Physiology · doi:10.1113/jphysiol.2014.282871 · Cited by 137
Findling, J. W., & Raff, H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0946 · Cited by 134 · cited 2×
“However, if there is diagnostic uncertainty, a 48-hour 2 mg/d DST or secondary tests can be performed, including DDAVP stimulation, and dexamethasone-CRH testing (1, 3, 56-58).”
BackgroundMethodTomlinson, J. W., Finney, J., Gay, C., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0495 · Cited by 131
Bilateral inferior petrosal sinus sampling
Zampetti, B., Grossrubatscher, E., Dalino Ciaramella, P., Boccardi, E., & Loli, P. (2016) · Endocrine Connections · doi:10.1530/ec-16-0029 · Cited by 130 · cited 1×
“Sensitivity can be increased by obtaining ACTH levels under CRH stimulation (1, 76, 78).”
BackgroundLC‐MS/MS‐based method for long‐term steroid profiling in human scalp hair
Noppe, G., de Rijke, Y. B., Dorst, K., van den Akker, E. L. T., & van Rossum, E. F. C. (2015) · Clinical Endocrinology · doi:10.1111/cen.12781 · Cited by 127
Manenschijn, L., Koper, J. W., van den Akker, E. L. T., de Heide, L. J. M., Geerdink, E. A. M., de Jong, F. H., Feelders, R. A., & van Rossum, E. F. C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1852 · Cited by 122
Self-citationCushing's syndrome: Overview of clinical presentation, diagnostic tools and complications
Barbot, M., Zilio, M., & Scaroni, C. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101380 · Cited by 116
Non-invasive Diagnostic Strategy in ACTH-dependent Cushing’s Syndrome
Frete, C., Corcuff, J.-B., Kuhn, E., Salenave, S., Gaye, D., Young, J., Chanson, P., & Tabarin, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa409 · Cited by 110 · cited 6×
“However, using these dynamic tests in combination with pituitary MRI can improve clinical accuracy, decreasing the need for BIPSS (9, 75).”
BackgroundMethodInfluentialComorbidities in Cushing’s disease
Sharma, S. T., Nieman, L. K., & Feelders, R. A. (2015) · Pituitary · doi:10.1007/s11102-015-0645-6 · Cited by 101
Self-citationDifferentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests
Alwani, R. A., Schmit Jongbloed, L. W., de Jong, F. H., van der Lely, A. J., de Herder, W. W., & Feelders, R. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0702 · Cited by 98
Self-citationFaggiano, A., Pivonello, R., Melis, D., Filippella, M., Di Somma, C., Petretta, M., Lombardi, G., & Colao, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021494 · Cited by 98
Environmental inhibitors of 11β-hydroxysteroid dehydrogenase type 2
Ma, X., Lian, Q.-Q., Dong, Q., & Ge, R.-S. (2011) · Toxicology · doi:10.1016/j.tox.2011.04.007 · Cited by 94
Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center
Yaneva, M., Kalinov, K., & Zacharieva, S. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0320 · Cited by 93 · cited 1×
“5 to 5 times increased mortality risk compared with the general population (7-11).”
BackgroundAntiretroviral and immunosuppressive drug-drug interactions: An update
Izzedine, H., Launay-Vacher, V., Baumelou, A., & Deray, G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00772.x · Cited by 86
Brue, T., Amodru, V., & Castinetti, F. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-1058 · Cited by 85
Cushing's syndrome: aftermath of the cure
Pivonello, R., De Martino, M. C., De Leo, M., Tauchmanovà, L., Faggiano, A., Lombardi, G., & Colao, A. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800025 · Cited by 85 · cited 1×
“Surgical remission does not eliminate the risk of complications from systemic comorbidities completely (12, 13).”
BackgroundQuality of Life in Patients With Cushing's Disease
Vives, A. S., Resmini, E., Martínez-Momblán, M.-A., Valassi, E., Martel‐Duguech, L., & Webb, S. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00862 · Cited by 76
Lopes, L. M. L., Francisco, R. P. V., Galletta, M. A. K., & Bronstein, M. D. (2016) · Pituitary · doi:10.1007/s11102-015-0680-3 · Cited by 70 · cited 3×
“9 nmol/L) for the third trimester (90, 95).”
BackgroundSuarez, M. G., Stack, M., Hinojosa-Amaya, J. M., Mitchell, M. D., Varlamov, E. V., Yedinak, C. G., Cetas, J. S., Sheppard, B., & Fleseriu, M. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz033 · Cited by 68
Approach to patients with pseudo-Cushing’s states
Scaroni, C., Albiger, N. M., Palmieri, S., Iacuaniello, D., Graziadio, C., Damiani, L., Zilio, M., Stigliano, A., Colao, A., Pivonello, R., et al. (2020) · Endocrine Connections · doi:10.1530/ec-19-0435 · Cited by 68
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
Clinical consequences of Cushing’s syndrome
Valassi, E., Crespo, I., Vives, A. S., & Webb, S. M. (2012) · Pituitary · doi:10.1007/s11102-012-0394-8 · Cited by 65
Savas, M., Muka, T., Wester, V. L., van den Akker, E. L. T., Visser, J. A., Braunstahl, G.-J., Slagter, S. N., Wolffenbuttel, B. H. R., Franco, O. H., & van Rossum, E. F. C. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01133 · Cited by 58 · cited 2×
“In this light, it is of interest that we recently showed associations between use of local corticosteroids, particularly inhaled types, and higher likelihood of metabolic syndrome, higher body mass index, reduced executive cognitive functioning, and a higher likelihood of mood and anxiety disorders (37, 38).”
BackgroundSelf-citationMortality in Cushing’s Disease
Clayton, R. N. (2010) · Neuroendocrinology · doi:10.1159/000315813 · Cited by 58 · cited 1×
“5 to 5 times increased mortality risk compared with the general population (7-11).”
BackgroundSavas, M., Vinkers, C. H., Rosmalen, J. G. M., Hartman, C. A., Wester, V. L., van den Akker, E. L. T., Iyer, A. M., McEwen, B. S., & van Rossum, E. F. C. (2020) · Neuroendocrinology · doi:10.1159/000501617 · Cited by 55
Self-citationWalia, R., Gupta, R., Bhansali, A., Pivonello, R., Kumar, R., Singh, H., Ahuja, C., Chhabra, R., Singh, A., Dhandapani, S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa755 · Cited by 53 · cited 1×
“100% of Cushing disease cases, including culprit lesions less than 6 mm in size, and was able to provide accurate information regarding lateralization and planning for intraoperative navigation, making it useful in both evaluation and management of ACTH-dependent CS (80).”
BackgroundPerlman, J. E., Johnston, P. C., Hui, F., Mulligan, G., Weil, R. J., Recinos, P. F., Yogi-Morren, D., Salvatori, R., Mukherjee, D., Gallia, G., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab012 · Cited by 50 · cited 4×
“There can also be serious complications, including stroke and subarachnoid hemorrhage, thought to be related to anatomical variations causing transient hypotension and/or vascular injury during the procedure (77).”
BackgroundMethodInfluentialAdrenocortical hyperplasia: A multifaceted disease
Bourdeau, I., Parisien-La Salle, S., & Lacroix, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101386 · Cited by 48
van Rossum, E. F. C., & van den Akker, E. L. T. (2011) · Endocrine Development · doi:10.1159/000321234 · Cited by 47
Self-citationMini-review of hair cortisol concentration for evaluation of Cushing syndrome
Hodes, A., Meyer, J., Lodish, M. B., Stratakis, C. A., & Zilbermint, M. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1517043 · Cited by 46
Ceccato, F., Antonelli, G., Frigo, A. C., Regazzo, D., Plebani, M., Boscaro, M., & Scaroni, C. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0644-8 · Cited by 44 · cited 7×
“MACS is often accompanied by cushingoid features, in particular, common cardiometabolic and mental complications, such as hypertension, type 2 diabetes, obesity, dyslipidemia, atrial fibrillation, and psychiatric or neurocognitive symptoms (86).”
MethodInfluentialStrategies for the Characterization of Disorders in Cortisol Sensitivity
Russcher, H., Smit, P., van Rossum, E. F. C., van den Akker, E. L. T., Brinkmann, A. O., de Heide, L. J. M., de Jong, F. H., Koper, J. W., & Lamberts, S. W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2212 · Cited by 43
Broersen, L. H. A., Andela, C. D., Dekkers, O. M., Pereira, A. M., & Biermasz, N. R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01054 · Cited by 42 · cited 1×
“Even if improvements occur after successful treatment, recovery often does not seem to be complete, and physical and neuropsychological comorbidities may persist (29).”
BackgroundCardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
Savas, M., Wester, V. L., de Rijke, Y. B., Rubinstein, G., Zopp, S., Dorst, K., van den Berg, S. A. A., Beuschlein, F., Feelders, R. A., Reincke, M., et al. (2019) · Neuroendocrinology · doi:10.1159/000498886 · Cited by 41 · cited 5×
“In these studies, a 3-cm hair sample per patient was used (corresponding to mean glucocorticoid levels of roughly past 3 months) and hair analysis was performed with either immunoassay (59, 61) or liquid chromatographytandem mass spectrometry (48, 66).”
BackgroundMethodInfluentialSelf-citationScalp hair cortisol for diagnosis of Cushing's syndrome
Wester, V. L., Reincke, M., Koper, J. W., van den Akker, E. L. T., Manenschijn, L., Berr, C. M., Fazel, J., de Rijke, Y. B., Feelders, R. A., & van Rossum, E. F. C. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0873 · Cited by 39 · cited 14×
“Endocrine evaluation revealed the following results: UFC values of 4.5 to 5.0 times ULN, a DST with a cortisol level of 17.33 µg/dL (478 nmol/L), and an ACTH concentration of 19.07 pg/mL (4.2 pmol/L).”
BackgroundMethodInfluentialSelf-citationThe morning and late‐night salivary cortisol ranges for healthy women may be used in pregnancy
Ambroziak, U., Kondracka, A., Bartoszewicz, Z., Krasnodębska‐Kiljańska, M., & Bednarczuk, T. (2015) · Clinical Endocrinology · doi:10.1111/cen.12853 · Cited by 38
Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses
Yozamp, N., & Vaidya, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101491 · Cited by 33
Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing’s Syndrome
Nieman, L. K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab046 · Cited by 33 · cited 1×
“Because of decreased glucocorticoid negative feedback effects, plasma ACTH levels will be inappropriately normal or elevated (generally > 20 pg/mL) in ACTH-dependent causes and low (generally < 10 pg/mL) in ACTH-independent causes of CS (70, 71).”
BackgroundInferior petrosal sinus sampling in Cushing’s syndrome: usefulness and pitfalls
Vassiliadi, D. A., Mourelatos, P., Kratimenos, T., & Tsagarakis, S. (2021) · Endocrine · doi:10.1007/s12020-021-02764-4 · Cited by 31 · cited 16×
“The high-dose DST is most often negative in patients with EAS (74).”
BackgroundInfluentialHair cortisol and cortisone measurements for the diagnosis of overt and mild Cushing's syndrome
Brossaud, J., Charret, L., De Angeli, D., Haissaguerre, M., Ferriere, A., Puerto, M., Gatta-Cherifi, B., Corcuff, J.-B., & Tabarin, A. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1127 · Cited by 29 · cited 3×
“In addition, hair cortisol and cortisone have been shown to contribute to the identification of patients with mild or subclinical CS (66).”
BackgroundMethodScreening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma
Toini, A., Dolci, A., Ferrante, E., Verrua, E., Malchiodi, E., Sala, E., Lania, A. G., Chiodini, I., Beck-Peccoz, P., Arosio, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0599 · Cited by 26
Tani, Y., Sugiyama, T., Izumiyama, H., Yoshimoto, T., Yamada, S., & Hirata, Y. (2011) · Endocrine Journal · doi:10.1507/endocrj.k10e-389 · Cited by 25 · cited 1×
“Patients with EAS are typically unresponsive although some tumors, in particular bronchial carcinoids can express CRH receptors (9, 74, 81, 82).”
BackgroundGlucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids
Santen, R. J., Jewell, C. M., Yue, W., Heitjan, D. F., Raff, H., Katen, K. S., & Cidlowski, J. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00352 · Cited by 25 · cited 3×
“Suspected unreported exogenous glucocorticoid administration can be detected with urinary or blood mass spectrometry assays designed to detect exogenous glucocorticoids (31).”
BackgroundMetabolic changes in serum steroids for diagnosing and subtyping Cushing’s syndrome
Ahn, C. H., Lee, C., Shim, J., Kong, S. H., Kim, S.-J., Kim, Y. H., Lee, K. E., Shin, C. S., Kim, J. H., & Choi, M. H. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105856 · Cited by 21 · cited 1×
“Corticotroph tumors are sensitive to CRH stimulation and a substantial ACTH and cortisol increase (> 50% of baseline) are compatible with a pituitary cause (83, 84).”
BackgroundCushing’s syndrome in pregnancy
Nassi, R., Ladu, C., Vezzosi, C., & Mannelli, M. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.984680 · Cited by 16
Broersen, L. H. A., Andela, C. D., Dekkers, O. M., Pereira, A., & Biermasz, N. R. (2019) · Leiden Repository (Leiden University) · Cited by 16
de Graaf, A. J., Mulder, A. L., & Krabbe, J. G. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219870834 · Cited by 14 · cited 1×
“In case of positive DST, measurement of serum dexamethasone concentration could be of value in identifying insufficient levels (53) (eg, from altered dexamethasone metabolism or inadequate test adherence) and in determining in whom a second DST would be useful (54).”
BackgroundSchneider, H. J., Dimopoulou, C., Stalla, G. K., Reincke, M., & Schopohl, J. (2013) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04488.x · Cited by 13
Savas, M., Wester, V. L., van der Voorn, B., Iyer, A. M., Koper, J. W., van den Akker, E. L. T., & van Rossum, E. F. C. (2021) · Neuroendocrinology · doi:10.1159/000513703 · Cited by 13 · cited 1×
“Interestingly, the adverse effects were less pronounced in corticosteroid users harboring gene polymorphisms, which are associated with glucocorticoid receptor resistance (39).”
BackgroundSelf-citationThe diagnosis and management of Cushing syndrome during pregnancy
Dong, D., Li, H., & Xiao, H. (2015) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2014.937331 · Cited by 12 · cited 2×
“Therefore, while 24-hour UFC can be unaffected during the first trimester, it may not be a reliable diagnostic test in the second and third trimesters, unless levels are significantly increased, up to 2- to 3-fold the upper limit of normal (3, 90, 92, 93).”
BackgroundAdrenocortical carcinoma masquerading as Cushing's disease
Jarial, K. D., Walia, R., Kumar, S., & Bhansali, A. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-217519 · Cited by 7
Does concomitant prolactin measurement ıncrease the accuracy of ınferior petrosal sinus sampling?
Apaydin, T., Yasar, M., Baltacioglu, F., Haklar, G., & Gogas Yavuz, D. (2022) · Neuroradiology · doi:10.1007/s00234-021-02886-6 · Cited by 6
(2020) · PubMed · Cited by 6
Self-citationMeasuring cortisol levels in hair: potential clinical applications in Cushing’s syndrome
van Rossum, E. F., Manenschijn, L., & Feelders, R. A. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.95 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Agrawal, 2021, The Human Hypothalamus, 185
Cited by
Gadelha, M., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 168
Ceccato, F., Barbot, M., Mondin, A., Boscaro, M., Fleseriu, M., & Scaroni, C. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac686 · Cited by 51
Determination of cortisone and cortisol in human scalp hair using an improved LC-MS/MS-based method
Mirzaian, M., van Zundert, S. K. M., Schilleman, W. F., Mohseni, M., Kuckuck, S., van Rossum, E. F. C., van Schaik, R. H. N., & van den Berg, S. A. A. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0341 · Cited by 41
Self-citationEmerging diagnostic methods and imaging modalities in cushing’s syndrome
Wright, K. E., van Rossum, E. F. C., Zan, E., Werner, N. L., Harris, A. G., Feelders, R. A., & Agrawal, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230447 · Cited by 33
“, diltiazem and fluoxetine) can prolong dexamethasone bioavailability, which can suppress ACTH production by adenomas that are sensitive to negative feedback and thus lead to false-negative results (13, 20).”
BackgroundResultInfluentialSelf-citationEpigenetic Mechanisms Modulated by Glucocorticoids With a Focus on Cushing Syndrome
Paes, T., Feelders, R. A., & Hofland, L. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae151 · Cited by 24
Self-citation
Metadata
- Authors
- Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A.
- Affiliations
- Erasmus MC (NL)
- NYU Langone Health (US)
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam , Rotterdam , The Netherlands
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-08-29
- Volume
- 107
- Issue
- 11
- Pages
- 3162-3174
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC9681610
- OpenAlex
- W4293457641
- Cited by
- 91
- References
- 100
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 17 · 2023: 12 · 2022: 2
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, endogenous Cushing syndrome, dexamethasone suppression test, 24-hour urinary free cortisol, late-night salivary cortisol, ACTH-dependent Cushing's syndrome, ACTH-independent Cushing's syndrome, plasma ACTH, inferior petrosal sinus sampling, hypercortisolism
- MeSH terms
- Cushing Syndrome, Diagnosis, Differential, Glucocorticoids, Humans, Hydrocortisone, Petrosal Sinus Sampling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.